What is the Purpose of this Study?
To compare the effectiveness of rejection surveillance of heart transplant recipients with Prospera dd-cfDNA to rejection surveillance with endomyocardial biopsy (EMB) and histology in the first post-transplant year. To compare the rates of biopsy-associated complications between subjects managed with Prospera dd-cfDNA and subjects managed with surveillance EMB To compare the quality-of-life between heart transplant recipients managed with Prospera dd-cfDNA compared with surveillance EMB To describe miRNA expression in stable heart transplant recipients and changes in miRNA expression during episodes of AR and heart allograft dysfunction.
Eligibility
- 1. Age 18 years or older at the time of signing informed consent.
- 2. Undergoing transplant evaluation or currently on the heart transplant waiting list and expected to receive a heart transplant.
- 3. Able to read, understand and provide written informed consent. If the patient is unable to sign informed consent, a legally authorized representative (LAR) can consent on behalf of the patient.
- 4. Able and willing to comply with the study visit schedule, study procedures and study requirements.
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance with Cell-free DNA versus Endomyocardial Biopsy